Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.
Identifieur interne : 000080 ( an2020/Analysis ); précédent : 000079; suivant : 000081Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.
Auteurs : Aimee Coscarart [États-Unis] ; Julianna Martel [États-Unis] ; Michael P. Lee [États-Unis] ; Alun R. Wang [États-Unis]Source :
- Journal of cutaneous pathology [ 1600-0560 ] ; 2020.
Abstract
Pembrolizumab, an anti-programmed cell death-1 (PD-1) antibody preparation, has been shown to induce various dermatologic adverse events which may present with delayed onset or even after discontinuation of therapy. We report a 78-year-old female patient with a stage II lung adenocarcinoma treated with pembrolizumab, who developed lichenoid eruptions and multiple cutaneous plaque/nodular eruptions as pseudoepitheliomatous hyperplasia, during and up to 2 months after discontinuation of pembrolizumab therapy. Multiple skin biopsies revealed epidermal hyperplasia with hyperkeratosis, hypergranulosis, diffuse to patchy lichenoid lymphocyte infiltrate with scattered eosinophils and neutrophils, confluent to scant dyskeratosis of the lower epidermis, minimal to overt invagination, and cystic proliferation of squamous epithelium to papillomatosis with hypergranulosis and keratosis. Overall, multiple patterns were present with similarities to lichenoid drug eruption, lichen planus, early invasive squamous cell carcinoma, early keratoacanthoma, and verruca. However, the findings ultimately supported a diagnosis of hypertrophic lichen planus. All the lesions resolved with oral prednisone, hydroxychloroquine, and topical triamcinolone acetonide ointment 0.1%. In summary, our case shows that pembrolizumab can induce lichenoid eruption with pseudoepitheliomatous hyperplasia, and these lesions can clinically and pathologically mimic early invasive squamous cell carcinomas or keratoacanthomas.
DOI: 10.1111/cup.13587
PubMed: 31589773
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000029
- to stream PubMed, to step Curation: 000029
- to stream PubMed, to step Checkpoint: 000003
- to stream Ncbi, to step Merge: 000A83
- to stream Ncbi, to step Curation: 000A83
- to stream Ncbi, to step Checkpoint: 000A83
- to stream Main, to step Merge: 000080
- to stream Main, to step Curation: 000080
- to stream Main, to step Exploration: 000080
- to stream an2020, to step Extraction: 000080
Links to Exploration step
pubmed:31589773Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.</title><author><name sortKey="Coscarart, Aimee" sort="Coscarart, Aimee" uniqKey="Coscarart A" first="Aimee" last="Coscarart">Aimee Coscarart</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Department of Pathology and Dermatology, Tulane University, New Orleans</wicri:cityArea></affiliation></author><author><name sortKey="Martel, Julianna" sort="Martel, Julianna" uniqKey="Martel J" first="Julianna" last="Martel">Julianna Martel</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Department of Pathology and Dermatology, Tulane University, New Orleans</wicri:cityArea></affiliation></author><author><name sortKey="Lee, Michael P" sort="Lee, Michael P" uniqKey="Lee M" first="Michael P" last="Lee">Michael P. Lee</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Department of Pathology and Dermatology, Tulane University, New Orleans</wicri:cityArea></affiliation></author><author><name sortKey="Wang, Alun R" sort="Wang, Alun R" uniqKey="Wang A" first="Alun R" last="Wang">Alun R. Wang</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Department of Pathology and Dermatology, Tulane University, New Orleans</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:31589773</idno><idno type="pmid">31589773</idno><idno type="doi">10.1111/cup.13587</idno><idno type="wicri:Area/PubMed/Corpus">000029</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000029</idno><idno type="wicri:Area/PubMed/Curation">000029</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000029</idno><idno type="wicri:Area/PubMed/Checkpoint">000003</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000003</idno><idno type="wicri:Area/Ncbi/Merge">000A83</idno><idno type="wicri:Area/Ncbi/Curation">000A83</idno><idno type="wicri:Area/Ncbi/Checkpoint">000A83</idno><idno type="wicri:Area/Main/Merge">000080</idno><idno type="wicri:Area/Main/Curation">000080</idno><idno type="wicri:Area/Main/Exploration">000080</idno><idno type="wicri:Area/an2020/Extraction">000080</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.</title><author><name sortKey="Coscarart, Aimee" sort="Coscarart, Aimee" uniqKey="Coscarart A" first="Aimee" last="Coscarart">Aimee Coscarart</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Department of Pathology and Dermatology, Tulane University, New Orleans</wicri:cityArea></affiliation></author><author><name sortKey="Martel, Julianna" sort="Martel, Julianna" uniqKey="Martel J" first="Julianna" last="Martel">Julianna Martel</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Department of Pathology and Dermatology, Tulane University, New Orleans</wicri:cityArea></affiliation></author><author><name sortKey="Lee, Michael P" sort="Lee, Michael P" uniqKey="Lee M" first="Michael P" last="Lee">Michael P. Lee</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Department of Pathology and Dermatology, Tulane University, New Orleans</wicri:cityArea></affiliation></author><author><name sortKey="Wang, Alun R" sort="Wang, Alun R" uniqKey="Wang A" first="Alun R" last="Wang">Alun R. Wang</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Department of Pathology and Dermatology, Tulane University, New Orleans</wicri:cityArea></affiliation></author></analytic><series><title level="j">Journal of cutaneous pathology</title><idno type="eISSN">1600-0560</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pembrolizumab, an anti-programmed cell death-1 (PD-1) antibody preparation, has been shown to induce various dermatologic adverse events which may present with delayed onset or even after discontinuation of therapy. We report a 78-year-old female patient with a stage II lung adenocarcinoma treated with pembrolizumab, who developed lichenoid eruptions and multiple cutaneous plaque/nodular eruptions as pseudoepitheliomatous hyperplasia, during and up to 2 months after discontinuation of pembrolizumab therapy. Multiple skin biopsies revealed epidermal hyperplasia with hyperkeratosis, hypergranulosis, diffuse to patchy lichenoid lymphocyte infiltrate with scattered eosinophils and neutrophils, confluent to scant dyskeratosis of the lower epidermis, minimal to overt invagination, and cystic proliferation of squamous epithelium to papillomatosis with hypergranulosis and keratosis. Overall, multiple patterns were present with similarities to lichenoid drug eruption, lichen planus, early invasive squamous cell carcinoma, early keratoacanthoma, and verruca. However, the findings ultimately supported a diagnosis of hypertrophic lichen planus. All the lesions resolved with oral prednisone, hydroxychloroquine, and topical triamcinolone acetonide ointment 0.1%. In summary, our case shows that pembrolizumab can induce lichenoid eruption with pseudoepitheliomatous hyperplasia, and these lesions can clinically and pathologically mimic early invasive squamous cell carcinomas or keratoacanthomas.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Louisiane</li></region></list><tree><country name="États-Unis"><region name="Louisiane"><name sortKey="Coscarart, Aimee" sort="Coscarart, Aimee" uniqKey="Coscarart A" first="Aimee" last="Coscarart">Aimee Coscarart</name></region><name sortKey="Lee, Michael P" sort="Lee, Michael P" uniqKey="Lee M" first="Michael P" last="Lee">Michael P. Lee</name><name sortKey="Martel, Julianna" sort="Martel, Julianna" uniqKey="Martel J" first="Julianna" last="Martel">Julianna Martel</name><name sortKey="Wang, Alun R" sort="Wang, Alun R" uniqKey="Wang A" first="Alun R" last="Wang">Alun R. Wang</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/an2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000080 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/an2020/Analysis/biblio.hfd -nk 000080 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= an2020
|étape= Analysis
|type= RBID
|clé= pubmed:31589773
|texte= Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/an2020/Analysis/RBID.i -Sk "pubmed:31589773" \
| HfdSelect -Kh $EXPLOR_AREA/Data/an2020/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |